Cardiomyopathy prognosis after benznidazole treatment in chronic canine Chagas' disease

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 8, 2012, Pages 1987-1995

  Santos, Fabiane M ^a,b   Lima, Wanderson G ^a   Gravel, André S ^a   Martins, Tassiane A F ^a   Talvani, André ^a   Torres, Rosália M ^c   Bahia, Maria Terezinha ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Dog model; Echocardiography; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DISEASE COURSE; DNA DETERMINATION; DRUG EFFICACY; DRUG POTENCY; ECHOCARDIOGRAPHY; HEART FUNCTION; NONHUMAN; PARASITEMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGNOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMAL EXPERIMENTATION; ANIMALS; ANTIPROTOZOAL AGENTS; CHAGAS CARDIOMYOPATHY; CHRONIC DISEASE; DNA, PROTOZOAN; DOG DISEASES; DOGS; HEART; NITROIMIDAZOLES; PARASITEMIA; PROGNOSIS; TRYPANOSOMA CRUZI;

EID: 84864526711     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks135     Document Type: Article

References (38)

1. Chagas C. Nova entidade morbida do homen. Resumo geral dos estudos etiológicos e clínicos. Mem Inst Oswaldo Cruz 1911; 3: 219-75.
2. Tanowitz HB, Machado FS, Jelicks LA et al. Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Prog Cardiovasc Dis 2009; 51: 524-39.
3. Coura JR. Chagas disease: what is known and what is needed-a background article. Mem Inst Oswaldo Cruz 2007; 102(Suppl.1): 113-22.
4. Viotti RJ, Vigliano C, Laucella S et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 2004; 90: 655-60.
5. Biolo A, Ribiero AL, Clausell N. Chagas cardiomyopathy-where do we stand after a hundred years? Progress Cardiovasc Dis 2010; 52: 300-16.
6. Coura JR, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97: 3-24.
7. Guedes PM, Fietto JL, Lana M et al. Advances in Chagas disease chemotherapy. Anti-Infect Agents Med Chem 2006; 5: 175-86.
8. Cançado JR. Long term evaluation of etiological treatment of Chagas' disease with benznidazole. Rev Inst Med Trop São Paulo 2002; 44: 29-37.
9. Lauria-Pires L, Braga MS, Vexenat AC et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 2000; 63: 111-8.
10. Viotti R, Vigliano C, Armenti H et al. Treatment of chronic Chagas' disease with benznidazole: clinical and serological evaluation of patients with long-term follow-up. Am Heart J 1994; 127: 151-62.
11. Braga MS, Lauria-Pires L, Argañaraz ER et al. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop de São Paulo 2000; 42: 157-61.
12. Fabbro de Suasnábar D, Arias E, Streiger M et al. Evolutive behavior towards cardiomyophaty of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop São Paulo 2000; 42: 99-110.
13. Garcia S, Ramos CO, Senra JF et al. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 2005; 49: 1521-8.
14. Bustamante JM, Lo Presti MS, Rivarola HW et al. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy. Int J Atimicrob Agents 2007; 29: 733-7.
15. Caldas IS, Talvani A, Caldas S et al. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol Res 2008; 103: 413-21.
16. Guedes PM, Veloso VM, Tafuri WL et al. The dog as model for chemotherapy of the Chagas' disease. Acta Trop 2002; 84: 9-17.
17. Ávila HA, Sigman DS, Cohen LM et al. Polymerase chain reaction amplification of Trypanosoma cruzi kinetoplast minicircle DNA isolation from whole blood lysates: diagnosis of chronic Chagas' disease. Mol Biochem Parasitol 1991; 40: 211-22.
18. Acquatella H. Echocardiography in Chagas heart disease. Circulation 2007; 115: 1124-31.
19. Rossi A, Cicoira M, Zanolla L et al. Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 40: 1425-30.
20. Schiller NB, Shah PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-67.
21. Castro AM, Luquetti AO, Rassi A et al. Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection. Parasitol Res 2006; 99: 379-83.
22. Galvão LMC, Chiari E, Macedo AM et al. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. J Clin Microbiol 2003; 41: 5066-70.
23. Fragata Filho AA, da Silva MA, Boainain E. Ethiologic treatment of acute and chronic Chagas' disease. São Paulo Med J 1995; 113: 867-72.
24. Martins HR, Figueiredo LM, Valamiel-Silva JC et al. Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes. J Antimicrob Chemother 2008; 61: 1319-27.
25. Tarleton RL. Parasite persistence in the etiology of Chagas disease. Int J Parasitol 2001; 31: 550-4.
26. Marin-Neto JA, Cunha-Neto E, Maciel BC et al. Pathogenesis of chronic Chagas heart disease. Circulation 2007; 115: 1109-23.
27. Gutierrez FR, Guedes PM, Gazinelli RT et al. The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunol 2009; 31: 673-85.
28. Cianciulli TF, Lax JA, Saccheri MC et al. Early detection of left ventricular diastolic dysfunction in Chagas' disease. Cardiovasc Ultrasound 2006; 4: 18.
29. Pinto AS, Oliveira BM, Botoni FA et al. Myocardial dysfunction in chagasic patients with no apparent heart disease. Arq Bras Cardiol 2007; 89: 348-53.
30. Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 2007; 115: 1101-8.
31. Ribeiro AL, Moraes RS, Ribeiro JP et al. Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease. Am Heart J 2001; 141: 260-5.
32. Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 2009; 104 Suppl 1: 311-8.
33. Samudio M, Montenegro-James S, Cabral M et al. Cytokine responses in Trypanosoma cruzi-infected children in Paraguay. Am J Trop Med Hyg 1998; 58: 119-21.
34. D'Ávila DA, Guedes PM, Castro AM et al. Immunological imbalance between IFN-g and IL-10 levels in the sera of patients with the cardiac form of Chagas disease. Mem Inst Oswaldo Cruz 2009; 104: 100-5.
35. Guedes PMM, Veloso VM, Afonso LCC et al. Development of chronic cardiomyopathy in canine Chagas disease correlates with high IFN-g, TNF-a, and low IL-10 production during the acute infection phase. Vet Immunol Immunophatol 2009; 130: 43-52.
36. Ferreira RC, Ianni BM, Abel LC et al. Increased plasma levels of tumor necrosis factor-a in asymptomatic/" indeterminate" and Chagas disease cardiomyopathy patients. Mem Inst Oswaldo Cruz 2003; 98: 407-11.
37. Talvani A, Rocha MO, Barcelos LS et al. Elevated concentrations of CCL2 and tumor necrosis factor-a in chagasic cardiomyopathy. Clin Infect Dis 2004; 38: 943-50.
38. Lula JF, Rocha MO, Nunes MC et al. Plasma concentrations of tumor necrosis factor-a, tumor necrosis factor-related apoptosis-inducing ligand, and FasLigand/CD95L in patients with Chagas cardiomyopathy correlate with left ventricular dysfunction. Eur J Heart Fail 2009; 11: 825-31.